Medigene AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 86
- Market Cap
- $33.8M
- Website
- http://www.medigene.de
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
- Conditions
- Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)Myxoid LiposarcomaSynovial Sarcoma
- Interventions
- Drug: LymphodepletionBiological: TCR-T cells (MDG1015)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 55
- Registration Number
- NCT06748872
- Locations
- 🇺🇸
Fred Hutch Cancer Center, Seattle, Washington, United States
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
- Conditions
- Acute Lymphoid LeukemiaMyeloproliferative DisordersAcute Myeloid LeukemiaMyelofibrosisMultiple MyelomaMyelodysplastic SyndromesChronic Myeloid LeukemiaMalignant Lymphoma
- Interventions
- Drug: MDG1021 dose 1Drug: MDG1021 dose 2Drug: MDG1021 dose 3Drug: MDG1021 optimal dose
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Medigene AG
- Registration Number
- NCT04464889
- Locations
- 🇳🇱
Leiden University Medical Centre, Leiden, Zuid Holland, Netherlands
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
- Conditions
- SafetyTolerabilityFeasibilityTreatment Efficacy
- Interventions
- Other: Investigator Choice therapy
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 9
- Registration Number
- NCT03503968
- Locations
- 🇩🇪
University Hospital Dresden, Dresden, Germany
🇩🇪University Hospital Erlangen, Erlangen, Germany
🇩🇪University Hospital Frankfurt, Frankfurt, Germany
DC Vaccination for Post-remission Therapy in AML
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 20
- Registration Number
- NCT02405338
- Locations
- 🇳🇴
Oslo University Hospital, Rikshospitalet, Oslo, Norway
News
Medigene and EpimAb Partner to Develop Novel TCR-Guided T Cell Engagers for Solid Tumors
• Medigene AG and EpimAb Biotherapeutics have formed a strategic co-development partnership to create off-the-shelf T cell receptor-guided T Cell Engagers (TCR-TCEs) for treating solid tumors and immune-related disorders. • The collaboration combines Medigene's 3S (sensitive, specific, safe) TCR technology with EpimAb's proprietary CD3 antibody and T-FIT platform to develop bispecific therapeutics with improved targeting precision and reduced off-target effects. • This partnership expands Medigene's TCR applications into off-the-shelf modalities, addressing a bispecific therapy market projected to exceed $80 billion by 2030 with a compound annual growth rate of 40.9%.
Medigene AG Refocuses Strategy on TCR-Guided Therapies, Pauses MDG1015 Trial
Medigene AG is prioritizing R&D efforts towards generating 3S TCRs for off-the-shelf TCR-guided therapies, aiming for sensitive, specific, and safe cancer treatments.